Patent application number | Description | Published |
20080227720 | Tumor cytotoxicity induced by modulators of the CXCR4 receptor - The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form. | 09-18-2008 |
20110052709 | NOVEL NANOPARTICLES FOR DELIVERY OF ACTIVE AGENTS - Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications. | 03-03-2011 |
20110052710 | NOVEL NANOPARTICLES FOR DELIVERY OF ACTIVE AGENTS - Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications. | 03-03-2011 |
20110081406 | ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine. | 04-07-2011 |
20110081407 | ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine. | 04-07-2011 |
20110081408 | ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine. | 04-07-2011 |
20110091528 | ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine. | 04-21-2011 |
20110091529 | ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine. | 04-21-2011 |
20110117107 | COMPOSITIONS AND METHODS FOR DIAGNOSIS, PROGNOSIS AND MANAGEMENT OF MALARIA - Biomarkers for predicting the severity of malaria and methods for their detection are disclosed. In one aspect, the present application discloses CXCL4, CXCL10, VEGF, PGDF, IL-1Ra, IL-8, MIP-1β, sFas, Fas-L, sTNF-R2, and sTNF-R1 as biomarkers for the severity of malaria. In another aspect, the present application discloses a method for determining the severity of malaria and predicting mortality due to cerebral malaria. The method comprises the detection of the biomarkers CXCL4 and/or CXCL10 and at least one more biomarker and determining the severity of malaria and predicting mortality due to cerebral malaria based upon the ratio of expression of the biomarkers in the subject versus the expression of the biomarkers in a control. | 05-19-2011 |
20110123603 | ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine. | 05-26-2011 |
20110150982 | ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine. | 06-23-2011 |
20110280871 | METHODS FOR PREVENTION AND TREATMENT OF INFLAMMATION USING ANTI-CHEMOKINE ANTIBODIES - It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines. | 11-17-2011 |
20110280872 | METHODS FOR PREVENTION AND TREATMENT OF INFLAMMATION USING ANTI-CHEMOKINE ANTIBODIES - It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines. | 11-17-2011 |
20120064089 | ANTI-CXCL16 AND ANTI-CXCR6 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND CANCER CELL MIGRATION - Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CXCL16 and/or the chemokine receptor CXCR6. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CXCL16 and/or the chemokine receptor CXCR6. | 03-15-2012 |
20120082993 | DETECTING CANCER WITH ANTI-CXCL16 AND ANTI-CXCR6 ANTIBODIES - Methods for detecting cancer or monitoring cancer progression in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL16 or CXCR6 or both CXCL16 and CXCR6. Also disclosed is a kit for detecting cancer or monitoring cancer progression. | 04-05-2012 |
20120100554 | DETECTING CANCER WITH ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES - Methods for detecting cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprise CCL25 or CCR9 or both CCL25 and CCR9. | 04-26-2012 |
20120128688 | ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND CANCER CELL MIGRATION - Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CXCL13 and/or the chemokine receptor CXCR5. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CXCL13 and/or the chemokine receptor CXCR5. | 05-24-2012 |
20130012415 | COMPOSITIONS AND METHODS FOR DIAGNOSIS, PROGNOSIS AND MANAGEMENT OF MALARIA - Biomarkers for predicting the severity of malaria and methods for their detection are disclosed. In one aspect, the present application discloses CXCL4, CXCL10, VEGF, PGDF, IL-1Ra, IL-8, MIP-1β, sFas, Fas-L, sTNF-R2, and sTNF-R1 as biomarkers for the severity of malaria. In another aspect, the present application discloses a method for determining the severity of malaria and predicting mortality due to cerebral malaria. The method comprises the detection of the biomarkers CXCL4 and/or CXCL10 and at least one more biomarker and determining the severity of malaria and predicting mortality due to cerebral malaria based upon the ratio of expression of the biomarkers in the subject versus the expression of the biomarkers in a control. | 01-10-2013 |
20130108647 | COMPOSITIONS AND METHODS FOR DIAGNOSIS, PROGNOSIS AND MANAGEMENT OF MALARIA | 05-02-2013 |